The fight against cancer is a collective combat
Cancer is the leading cause of death in France. With our subsidiary Orano Med, the Orano group is advancing research in nuclear medicine and new cancer therapies.
We have been resolutely committeed to this collective combat, both domestically and internationally, since 2012. As Orano Med starts up a new clinical trial in February 2018 in the United States, with its partner RadioMedix, CEO Julien Dodet underlines our belief: "we are convinced that Orano Med can have a major impact in the fight against cancer. At the crossroads of advanced nuclear technologies and the latest advances in medicine, we are developing innovative targeted alphatherapy treatments to overcome the disease."
Taking innovation ever further to save lives
Innovation is in Orano's DNA. It was the discovery of certain properties of the Thorium derived from our legacy industrial activities in the years 1950-1970, that the group decided to embark on research in nuclear medicine and alphatherapy, an innovative form of radiotherapy.
By combining high purity Lead-212, extracted from thorium, with a biological vector such as an antibody, alphatherapy is able to very precisely target cancer cells and destroy them without damaging neighboring healthy cells.
Orano Med is leveraging its know-how and expertise to pursue its development with the launch of a new production unit (currently in the design phase) that will add to the production capacity of the facilities at Bessines-sur-Gartempe (Limousin, France) and Plano (Texas, USA).
The fight against cancer continues!
Photo credits: Eric Larrayadieu / Orano